Christine Y. Lu, PhD


Cost Burden of Hepatitis C Virus Treatment in Commercially Insured Patients

December 13, 2019

Rates of hepatitis C virus (HCV) treatment in a commercially insured population doubled after availability of new direct-acting antivirals. Member out-of-pocket spending was kept low while the health plan bore 99% of spending on HCV medications.